Xilio Therapeutics (XLO) Current Assets (2020 - 2026)

Xilio Therapeutics has disclosed Current Assets across 7 years of filings, most recently posting $154.2 million for Q1 2026.

• Current Assets for Q1 2026 came in at $154.2 million, up 65.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.2 million (up 65.46% YoY), and the FY2025 annual result was $145.0 million, up 140.77% from the prior year.
• Current Assets came in at $154.2 million for Q1 2026 at Xilio Therapeutics, up from $145.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $181.1 million in Q1 2022 to a low of $48.1 million in Q4 2023.
• The 5-year median for Current Assets is $97.0 million (2023), against an average of $106.5 million.
• Across the five-year window, Current Assets sank 61.34% in 2023 and jumped 140.77% in 2025, its largest moves.
• Xilio Therapeutics' Current Assets stood at $124.5 million in 2022, then tumbled by 61.34% to $48.1 million in 2023, then rose by 25.16% to $60.2 million in 2024, then surged by 140.77% to $145.0 million in 2025, then gained by 6.33% to $154.2 million in 2026.
• The last three Current Assets figures came in at $154.2 million (Q1 2026), $145.0 million (Q4 2025), and $124.1 million (Q3 2025), per Business Quant data.